 IRVINE, CA ACCESSWIRE October 24, 2019 Hancock Jaffe Laboratories, Inc. HJLINASDAQ:HJLIW, a developer of medical devices that restore cardiac and vascular health, announced today that Dr. Jorge Hernando Ulloa, the Principal Investigator for HJLIs first-in-human VenoValve study in Bogota, Colombia, presents new six 6 month VenoValve data at the 20th Congress of Asian Society for Vascular Surgery in Bali, Indonesia. Dr. Ulloas presentation indicates that each of the first five 5 VenoValve patients continued to improve in all study end-points at six 6 months post VenoValve surgical implant, including average improvements of an additional ten 10 percentage points in reflux, two 2 percentage points in disease manifestations VCSS scores, and thirteen 13 percentage points in pain VAS scores, compared to levels at ninety 90 days post VenoValve surgeries. 